TriangleRELY-30 (NCT02917083)
RELY-30 trial for Hodgkin's Lymphoma (NCT02917083). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Hodgkin lymphoma is usually cured. When it keeps returning after chemotherapy, antibodies, and transplant, the choices thin out.
The idea: take the antibody that already targets Hodgkin cells, and bolt it onto the patient's own T cells.
Hodgkin cells carry a marker called CD30. Antibody drugs against it help but rarely cure. Here, T cells from the patient's blood receive a gene that mounts the anti-CD30 antibody on their surface, so each cell hunts on its own. One infusion, after chemotherapy clears room.
In forty-one heavily treated patients at two centers, side effects were mostly on blood counts, and after fludarabine-based chemotherapy, seven in ten responded, most completely.
RELY-30, at Baylor, led by Carlos Ramos, now tests higher doses. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.